Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Depression in Young Women: Often There, Often Overlooked

Published: Fri, 20 Apr 2018 10:15:17 EDT
Dr. Arefa Cassoobhoy highlights a gap in treating depression in young women.
Medscape Internal Medicine

Marijuana and the Developing Brain: Current State of Evidence

Published: Fri, 20 Apr 2018 10:06:34 EDT
What do we know about the effect of marijuana on the adolescent brain?
Medscape Pediatrics

Delabeling for Penicillin Allergy Found Safe in Children

Published: Fri, 20 Apr 2018 08:02:52 EDT
Children with low-risk penicillin allergy symptoms who tested negative for penicillin allergy tolerated penicillin without serious adverse or allergic reactions during the following year, a study found.
Medscape Medical News

CMS Should Have Required a Randomized Trial of F1CDx

Published: Fri, 20 Apr 2018 12:00:00 EDT
Authors give five reasons why CMS should have refrained from coverage of a 324-gene panel offered by Foundation Medicine in the absence of a randomized trial.
Annals of Oncology
Displaying results 17-20 (of 20)
 1 - 2 - 3 - 4 - 5 


Oncolytics Biotech’s CMO departs on cusp of phase 3 trial

Published: Wed, 18 Apr 2018 12:37:45 +0000
Oncolytics Biotech has lost its CMO shortly before it is due to start a pivotal metastatic breast cancer trial. Andres Gutierrez, M.D., Ph.D., is leaving to pursue other opportunities after spending 18 months as CMO of the Canadian microcap.

Johnson & Johnson scraps phase 3 antibiotic program acquired in $30B Actelion takeover

Published: Tue, 17 Apr 2018 12:54:18 +0000
Johnson & Johnson has halted development of cadazolid in clostridium difficile-associated diarrhea. The antibiotic was one of two experimental assets J&J acquired in its $30 billion takeover of Actelion last year.

Basilea slots ArQule FGF drug into its cancer portfolio

Published: Tue, 17 Apr 2018 12:50:57 +0000
Deal-hungry Basilea has extended its cancer pipeline by licensing ArQule’s derazantinib, a phase 2-ready drug that slots in ahead of its in-house oncology programs.

J&J buys into Bristol-Myers cardiovascular disease program

Published: Tue, 17 Apr 2018 12:09:41 +0000
Johnson & Johnson has bought into Bristol-Myers Squibb’s Factor XIa inhibitor program. The deal gives J&J a stake in the development and potential commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.
Displaying results 17-20 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy